The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The recent approval of tafasitamab, lenalidomide and rituximab for patients with R/R FL
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, shares insights into the recent FDA approval of tafasitamab in combination with lenalidomide and rituximab for patients with relapsed/refractory (R/R) follicular lymphoma (FL). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so very exciting for patients. Tafa-len rituximab combination approved based on the InMIND study. That was a study comparing that triplet combination to lenalidomide and rituximab. The overall study demonstrated improvement in progression-free survival with a median PFS of 22 months for Tafa-len and rituximab compared to around 12 months for lenalidomide and rituximab, which is a very commonly used second-line therapy in the community setting...
Yeah, so very exciting for patients. Tafa-len rituximab combination approved based on the InMIND study. That was a study comparing that triplet combination to lenalidomide and rituximab. The overall study demonstrated improvement in progression-free survival with a median PFS of 22 months for Tafa-len and rituximab compared to around 12 months for lenalidomide and rituximab, which is a very commonly used second-line therapy in the community setting. So I think with that in mind, as well as the fact that toxicity really did not look very different with the triplet, I think we’ll see with this approval that there’ll be a shift towards more use of tafasitamab, lenalidomide, and rituximab in follicular lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
